Does Rallies show Form 4 insider transactions for KRYS?

Yes. Rallies tracks KRYS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is KRYS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KRYS. It does not provide personalized investment advice.

KRYS (Krystal Biotech, Inc. Common Stock) Stock Analysis - Insider Trades

Krystal Biotech, Inc. Common Stock (KRYS) is a publicly traded Healthcare sector company. As of May 20, 2026, KRYS trades at $296.05 with a market cap of $8.60B and a P/E ratio of 38.58. KRYS moved +3.00% today. Year to date, KRYS is +23.43%; over the trailing twelve months it is +129.62%. Its 52-week range spans $122.80 to $319.48. Analyst consensus is strong buy with an average price target of $316.00. Rallies surfaces KRYS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading KRYS stock inside the company?

Recent KRYS insider activity includes Krishnan Suma sold 407, Krishnan Suma sold 589, Krishnan Suma sold 668, Krishnan Suma sold 3.67K, and Krishnan Suma sold 2.93K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

KRYS Key Metrics

Key financial metrics for KRYS
Metric	Value
Price	$296.05
Market Cap	$8.60B
P/E Ratio	38.58
EPS	$7.75
Dividend Yield	0.00%
52-Week High	$319.48
52-Week Low	$122.80
Volume	170.35K
Avg Volume	0
Revenue (TTM)	$417.30M
Net Income	$225.03M
Gross Margin	0.00%

Recent KRYS Insider Trades

Krishnan Suma sold 407 (~$104.73K) on Mar 4, 2026.
Krishnan Suma sold 589 (~$152.28K) on Mar 4, 2026.
Krishnan Suma sold 668 (~$173.42K) on Mar 4, 2026.
Krishnan Suma sold 3.67K (~$954.76K) on Mar 4, 2026.
Krishnan Suma sold 2.93K (~$766.20K) on Mar 4, 2026.

Latest KRYS News

Krystal Biotech jumps as Q1 VYJUVEK revenue hits $116.4M, pipeline catalysts build — May 5, 2026
Krystal Biotech drops as investors digest Q1 update despite $116.4M VYJUVEK revenue — May 4, 2026
Krystal Biotech Logs 32% VYJUVEK Revenue Growth, Strengthens Pipeline with KB803 Enrollment — May 4, 2026
Krystal Biotech to Unveil KB409/410 PCD Data and KB407, KB707 Trial Updates — Apr 30, 2026
Krystal Biotech drops as traders trim exposure ahead of early-May earnings report — Apr 29, 2026

KRYS Analyst Consensus

10 analysts cover KRYS: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $316.00.

Common questions about KRYS

Who is trading KRYS stock inside the company?: Recent KRYS insider activity includes Krishnan Suma sold 407, Krishnan Suma sold 589, Krishnan Suma sold 668, Krishnan Suma sold 3.67K, and Krishnan Suma sold 2.93K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for KRYS?: Yes. Rallies tracks KRYS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is KRYS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KRYS. It does not provide personalized investment advice.